250 related articles for article (PubMed ID: 26773108)
1. Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic Arthritis.
Mease PJ; Genovese MC; Mutebi A; Viswanathan HN; Chau D; Feng J; Erondu N; Nirula A
J Rheumatol; 2016 Feb; 43(2):343-9. PubMed ID: 26773108
[TBL] [Abstract][Full Text] [Related]
2. Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials.
Gottlieb AB; Gordon K; Hsu S; Elewski B; Eichenfield LF; Kircik L; Rastogi S; Pillai R; Israel R
J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1305-1313. PubMed ID: 29512200
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis.
Papp K; Menter A; Strober B; Kricorian G; Thompson EH; Milmont CE; Nirula A; Klekotka P
J Am Acad Dermatol; 2015 Mar; 72(3):436-439.e1. PubMed ID: 25553889
[TBL] [Abstract][Full Text] [Related]
4. Reliability and Validity of the Psoriasis Symptom Inventory in Patients With Psoriatic Arthritis.
Wilson HD; Mutebi A; Revicki DA; Mease PJ; Genovese MC; Erondu N; Nirula A; Yuan FJ; Viswanathan HN
Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1750-6. PubMed ID: 26206134
[TBL] [Abstract][Full Text] [Related]
5. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.
Mease PJ; Genovese MC; Greenwald MW; Ritchlin CT; Beaulieu AD; Deodhar A; Newmark R; Feng J; Erondu N; Nirula A
N Engl J Med; 2014 Jun; 370(24):2295-306. PubMed ID: 24918373
[TBL] [Abstract][Full Text] [Related]
6. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
[TBL] [Abstract][Full Text] [Related]
7. Brodalumab Is Associated with High Rates of Complete Clearance and Quality of Life Improvement: A Subgroup Analysis of Patients with Psoriasis and Concomitant Psoriatic Arthritis.
Kokolakis G; Vadstrup K; Hansen JB; Carrascosa JM
Dermatology; 2022; 238(4):620-629. PubMed ID: 34823247
[TBL] [Abstract][Full Text] [Related]
8. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
Spuls PI; Hooft L
Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
[TBL] [Abstract][Full Text] [Related]
9. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study.
Nakagawa H; Niiro H; Ootaki K;
J Dermatol Sci; 2016 Jan; 81(1):44-52. PubMed ID: 26547109
[TBL] [Abstract][Full Text] [Related]
10. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.
Papp KA; Leonardi C; Menter A; Ortonne JP; Krueger JG; Kricorian G; Aras G; Li J; Russell CB; Thompson EH; Baumgartner S
N Engl J Med; 2012 Mar; 366(13):1181-9. PubMed ID: 22455412
[TBL] [Abstract][Full Text] [Related]
11. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.
Papp KA; Reich K; Paul C; Blauvelt A; Baran W; Bolduc C; Toth D; Langley RG; Cather J; Gottlieb AB; Thaçi D; Krueger JG; Russell CB; Milmont CE; Li J; Klekotka PA; Kricorian G; Nirula A
Br J Dermatol; 2016 Aug; 175(2):273-86. PubMed ID: 26914406
[TBL] [Abstract][Full Text] [Related]
12. Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials.
Mease PJ; Helliwell PS; Hjuler KF; Raymond K; McInnes I
Ann Rheum Dis; 2021 Feb; 80(2):185-193. PubMed ID: 33106286
[TBL] [Abstract][Full Text] [Related]
13. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
Lebwohl M; Strober B; Menter A; Gordon K; Weglowska J; Puig L; Papp K; Spelman L; Toth D; Kerdel F; Armstrong AW; Stingl G; Kimball AB; Bachelez H; Wu JJ; Crowley J; Langley RG; Blicharski T; Paul C; Lacour JP; Tyring S; Kircik L; Chimenti S; Callis Duffin K; Bagel J; Koo J; Aras G; Li J; Song W; Milmont CE; Shi Y; Erondu N; Klekotka P; Kotzin B; Nirula A
N Engl J Med; 2015 Oct; 373(14):1318-28. PubMed ID: 26422722
[TBL] [Abstract][Full Text] [Related]
14. Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory.
Gordon KB; Kimball AB; Chau D; Viswanathan HN; Li J; Revicki DA; Kricorian G; Ortmeier BG
Br J Dermatol; 2014 Mar; 170(3):705-15. PubMed ID: 24079852
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double-blind, placebo-controlled study.
Seo SJ; Shin BS; Lee JH; Jeong H
J Dermatol; 2021 Jun; 48(6):807-817. PubMed ID: 33373480
[TBL] [Abstract][Full Text] [Related]
16. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
Torii H; Nakagawa H;
J Dermatol Sci; 2010 Jul; 59(1):40-9. PubMed ID: 20547039
[TBL] [Abstract][Full Text] [Related]
17. Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis.
Viswanathan HN; Mutebi A; Milmont CE; Gordon K; Wilson H; Zhang H; Klekotka PA; Revicki DA; Augustin M; Kricorian G; Nirula A; Strober B
Value Health; 2017 Sep; 20(8):1174-1179. PubMed ID: 28964451
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial.
Papp KA; Blauvelt A; Kimball AB; Han C; Randazzo B; Wasfi Y; Shen YK; Li S; Griffiths CEM
J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1515-1522. PubMed ID: 29512196
[TBL] [Abstract][Full Text] [Related]
19. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
Antoni C; Krueger GG; de Vlam K; Birbara C; Beutler A; Guzzo C; Zhou B; Dooley LT; Kavanaugh A;
Ann Rheum Dis; 2005 Aug; 64(8):1150-7. PubMed ID: 15677701
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials.
McMichael A; Desai SR; Qureshi A; Rastogi S; Alexis AF
Am J Clin Dermatol; 2019 Apr; 20(2):267-276. PubMed ID: 30471012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
